Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel plus biweekly cetuximab for platinum- and ICI-refractory head and neck cancer
jRCTs051200040Completed
- Start
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of paclitaxel and cetuximab in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Objective response. Started Aug 2020; status: completed.
02
Drugs
paclitaxelcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs051200040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051200040.